Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).

Autor: Severance R; Synexus Clinical Research, Chandler, AZ, USA., Schwartz H; Research Centers of America, Hollywood, FL, USA., Dagan R; Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel., Connor L; Merck & Co., Inc., Kenilworth, NJ, USA., Li J; Merck & Co., Inc., Kenilworth, NJ, USA., Pedley A; Merck & Co., Inc., Kenilworth, NJ, USA., Hartzel J; Merck & Co., Inc., Kenilworth, NJ, USA., Sterling TM; Merck & Co., Inc., Kenilworth, NJ, USA., Nolan KM; Merck & Co., Inc., Kenilworth, NJ, USA., Tamms GM; Merck & Co., Inc., Kenilworth, NJ, USA., Musey LK; Merck & Co., Inc., Kenilworth, NJ, USA., Buchwald UK; Merck & Co., Inc., Kenilworth, NJ, USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 1-14. Date of Electronic Publication: 2021 Nov 02.

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.

Autor: Buchwald UK; Merck & Co., Inc., Kenilworth, NJ, USA., Andrews CP; Diagnostics Research Group, San Antonio, TX, USA., Ervin J; Alliance for Multispecialty Research, Knoxville, TN, USA., Peterson JT; Foothill Family Clinic, Salt Lake City, UT, USA., Tamms GM; Merck & Co., Inc., Kenilworth, NJ, USA., Krupa D; IQVIA, Durham, NC, USA., Ajiboye P; IQVIA, Durham, NC, USA., Roalfe L; University College London, London, UK., Krick AL; Merck & Co., Inc., Kenilworth, NJ, USA., Sterling TM; Merck & Co., Inc., Kenilworth, NJ, USA., Wang M; Merck & Co., Inc., Kenilworth, NJ, USA., Martin JC; Merck & Co., Inc., Kenilworth, NJ, USA., Stek JE; Merck & Co., Inc., Kenilworth, NJ, USA., Kohn MA; Merck & Co., Inc., Kenilworth, NJ, USA., Folaranmi T; Merck & Co., Inc., Kenilworth, NJ, USA., Abeygunawardana C; Merck & Co., Inc., Kenilworth, NJ, USA., Hartzel J; Merck & Co., Inc., Kenilworth, NJ, USA., Musey LK; Merck & Co., Inc., Kenilworth, NJ, USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Aug 03; Vol. 17 (8), pp. 2678-2690. Date of Electronic Publication: 2021 May 21.

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.

Autor: Platt HL; From the Merck & Co., Inc., Kenilworth, New Jersey., Greenberg D; Soroka Medical Center, Research, Beersheba, Israel., Tapiero B; CHU Sainte-Justine, Université de Montréal, Montréal, Québec, Canada., Clifford RA; Coastal Pediatric Research, Charleston, South Carolina., Klein NP; Kaiser Permanente Vaccine Study Center, Oakland, California., Hurley DC; Cottonwood Pediatrics, Research, Murray, Utah., Shekar T; From the Merck & Co., Inc., Kenilworth, New Jersey., Li J; From the Merck & Co., Inc., Kenilworth, New Jersey., Hurtado K; From the Merck & Co., Inc., Kenilworth, New Jersey., Su SC; From the Merck & Co., Inc., Kenilworth, New Jersey., Nolan KM; From the Merck & Co., Inc., Kenilworth, New Jersey., Acosta CJ; From the Merck & Co., Inc., Kenilworth, New Jersey., McFetridge RD; From the Merck & Co., Inc., Kenilworth, New Jersey., Bickham K; From the Merck & Co., Inc., Kenilworth, New Jersey., Musey LK; From the Merck & Co., Inc., Kenilworth, New Jersey.

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2020 Aug; Vol. 39 (8), pp. 763-770.

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.

Autor: Stacey HL; a Diablo Clinical Research, Inc , Walnut Creek , CA , USA., Rosen J; b Clinical Research of South Florida , Coral Gables , FL , USA., Peterson JT; c J. Lewis Research, Inc./Foothill Family Clinic , Salt Lake City , USA., Williams-Diaz A; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Gakhar V; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Sterling TM; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Acosta CJ; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Nolan KM; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Li J; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Pedley A; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Benner P; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Abeygunawardana C; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Kosinski M; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Smith WJ; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Pujar H; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA., Musey LK; d Merck & Co., Inc., Merck Research Laboratories , Kenilworth , NJ , USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2019; Vol. 15 (3), pp. 530-539. Date of Electronic Publication: 2019 Jan 16.

Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Autor: Ciprero KL; a Merck & Co., Inc. , Kenilworth , NJ , USA., Marchese RD; a Merck & Co., Inc. , Kenilworth , NJ , USA., Richard P; b Sanofi Pasteur-MSD , Lyon , France., Baudin M; b Sanofi Pasteur-MSD , Lyon , France., Sterling TM; a Merck & Co., Inc. , Kenilworth , NJ , USA., Manoff SB; a Merck & Co., Inc. , Kenilworth , NJ , USA., Radley D; a Merck & Co., Inc. , Kenilworth , NJ , USA., Stek JE; a Merck & Co., Inc. , Kenilworth , NJ , USA., Soubeyrand B; b Sanofi Pasteur-MSD , Lyon , France., Grabenstein JD; a Merck & Co., Inc. , Kenilworth , NJ , USA., Samson SI; b Sanofi Pasteur-MSD , Lyon , France., Musey LK; a Merck & Co., Inc. , Kenilworth , NJ , USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2016 Aug 02; Vol. 12 (8), pp. 2135-2141. Date of Electronic Publication: 2016 Mar 22.